shot-button
E-paper E-paper
Home > News > India News > Article > Brazil suspends Bharat Biotechs Covaxin order over graft allegations

Brazil suspends Bharat Biotech’s Covaxin order over graft allegations

Updated on: 30 June,2021 12:00 AM IST  |  Hyderabad
PTI |

The Covaxin contract to Brazil landed in controversy after the South American country's Attorney General reportedly launched a probe into the deal.

Brazil suspends Bharat Biotech’s Covaxin order over graft allegations

Photo used for representational purpose. Pic/AFP

The Brazilian government, which agreed to purchase 20 million doses of Bharat Biotech’s COVID-19 vaccine Covaxin, on Wednesday announced suspension of the contract following allegations of irregularities in the deal.


"By recommendation of @CGUonline, we decided to temporarily suspend the Covaxin contract. According to CGU''s preliminary analysis, there are no irregularities in the contract, but, due to compliance, the @minsaude opted to suspend the contract for further analysis," Brazil Health Minister Marcelo Queiroga tweeted.


The Covaxin contract to Brazil landed in controversy after the South American country's Attorney General reportedly launched a probe into the deal.


"It is noteworthy that the @govbr did not pay ANY CENT for the Covaxin vaccine. The measure does not compromise the pace of the vaccination campaign against #Covid19 in Brazil, since there is no approval from Anvisa for emergency or definitive use of the immunizing agent," Queiroga said in another tweet.

p>This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK